Allspring Global Investments Holdings LLC Buys 35,021 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Allspring Global Investments Holdings LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 922,960 shares of the biopharmaceutical company’s stock after buying an additional 35,021 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.07% of Gilead Sciences worth $67,607,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Altfest L J & Co. Inc. acquired a new position in Gilead Sciences during the 4th quarter worth about $210,000. Federated Hermes Inc. grew its stake in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after buying an additional 175,925 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Gilead Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after buying an additional 87,482 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at $74,000. Finally, Eagle Asset Management Inc. boosted its position in Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock worth $25,724,000 after purchasing an additional 60,697 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.3 %

Shares of NASDAQ GILD opened at $68.40 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The business has a fifty day simple moving average of $66.01 and a two-hundred day simple moving average of $72.42. The firm has a market cap of $85.22 billion, a PE ratio of 190.00, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period last year, the business posted $1.37 EPS. The business’s revenue was up 5.3% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.50%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Morgan Stanley reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Royal Bank of Canada reissued a “sector perform” rating and set a $74.00 target price on shares of Gilead Sciences in a research note on Monday. Robert W. Baird reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Maxim Group lowered their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $83.47.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.29% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.